

August 19, 2025

BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic's IzoView Device

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025, Izotropic Corporation (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**) ("**Izotropic**", or the "**Company**"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company's awareness initiatives.

BreastCT.com has been created as a central educational resource on dedicated breast CT technology and the Company's [IzoView Breast CT Imaging System](#), with a focus on its potential to address persistent challenges in detecting breast cancer in the 50% of women with dense breast tissue. With IzoView's engineering complete, the site is designed to evolve alongside the Company through clinical study preparation, U.S. and global regulatory phases, and ongoing education and awareness initiatives leading to commercial launch.

This new content positions Izotropic within a broader industry context by highlighting public companies that have successfully created and led new imaging categories. This approach gives audiences a clear frame of reference for where IzoView Breast CT could fit within an evolving market to build recognition ahead of future regulatory and commercial milestones.

At strategic times, Izotropic will integrate native advertising campaigns into BreastCT.com to help drive awareness in alignment with the Company's goals.

About Izotropic:

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com